Spike Protein Implicated in Post-COVID-19 Memory Loss
Summary: The spike protein that is responsible for COVID-19’s entry into cells could be responsible for post-COVID memory loss. Researchers identified the TLR4 receptor as a potential target for treating COVID-related memory loss.
Patients diagnosed with post-COVID-19 syndrome often experience cognitive and memory impairments. A new study by researchers from the Federal University of Rio de Janeiro (UFRJ) and UniRio provides insight into the mechanism behind this phenomenon.
The study suggests that the Spike protein, responsible for the virus’s entry into human cells, could be responsible for memory loss in post-COVID-19 syndrome.
The study also identifies TLR4 receptor as a potential therapeutic target for the symptoms.
The study involved experiments with mice, where the researchers infused the Spike protein from SARS-CoV-2 into the brains of the animals. The results showed that the infusion induced delayed memory impairment, similar to post-COVID-19 syndrome in humans.
The scientists observed an increase in the quantity and activation state of microglia, a type of brain cell involved in the innate immune response, and whose role is essential in neuroinflammatory diseases.
The study leaders, Claudia Figueiredo and Giselle Passos from the UFRJ’s School of Pharmacy, explained that the activation of the TRL4 receptor by the viral protein induces neuroinflammation, leading to the elimination of synaptic proteins by microglia through a phagocytosis process.
This results in memory impairment. The phenomenon was observed in both mice and humans, and patients with polymorphisms in the gene related to TLR4 were found to have a higher risk of developing late memory impairments after SARS-CoV-2 infection.
The researchers concluded that the Spike protein has a central role in the development of cognitive changes after COVID-19 and suggested that TLR4 is a promising target for the development of preventive and therapeutic strategies to avoid or treat memory loss caused by SARS-CoV-2.
The study was funded by the Carlos Chagas Filho Foundation for Research Support of the State of Rio de Janeiro (Faperj), with scholarships financed by the Brazilian National Council for Scientific and Technological Development (CNPq) and the Coordination for the Improvement of Higher Education Personnel (Capes).
About this memory and COVID-19 research news
Author: Luana Rocha
Contact: Luana Rocha – INBEB
Image: The image is in the public domain
Original Research: Open access.
“SARS-CoV-2 Spike protein induces TLR4-mediated long-term cognitive dysfunction recapitulating post-COVID-19 syndrome in mice” by Claudia Figueiredo et al. Cell Reports
SARS-CoV-2 Spike protein induces TLR4-mediated long-term cognitive dysfunction recapitulating post-COVID-19 syndrome in mice
- Spike protein infusion into mouse brain induces late cognitive dysfunction
- Spike protein induces late hippocampal microgliosis and synapse loss
- Blockage of TLR4 renders mice resistant to Spike-induced cognitive dysfunction
- TLR4-2604G>A GG genotype was related to poor cognitive outcome in COVID-19 patients
Cognitive dysfunction is often reported in patients with post-coronavirus disease 2019 (COVID-19) syndrome, but its underlying mechanisms are not completely understood.
Evidence suggests that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike protein or its fragments are released from cells during infection, reaching different tissues, including the CNS, irrespective of the presence of the viral RNA.
Here, we demonstrate that brain infusion of Spike protein in mice has a late impact on cognitive function, recapitulating post-COVID-19 syndrome.
We also show that neuroinflammation and hippocampal microgliosis mediate Spike-induced memory dysfunction via complement-dependent engulfment of synapses.
Genetic or pharmacological blockage of Toll-like receptor 4 (TLR4) signaling protects animals against synapse elimination and memory dysfunction induced by Spike brain infusion. Accordingly, in a cohort of 86 patients who recovered from mild COVID-19, the genotype GG TLR4-2604G>A (rs10759931) is associated with poor cognitive outcome.
These results identify TLR4 as a key target to investigate the long-term cognitive dysfunction after COVID-19 infection in humans and rodents.